AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, IndiaRandomized Controlled Trial Published on 2022-06-012022-10-04 Journal: Complementary therapies in medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, [키워드] Adverse Analysis Ayurveda Care Chest clinical recovery conducted contributed control group COVID COVID-19 determine diagnosed disease double-blind drug effective Efficacy Final HRCT incidence India integrative medicine less metabolic functions Mild moderate Moderate COVID-19 negative RT-PCR Open-label outcome pandemic parallel-group participant Participants Patient pro-inflammatory proportion Proportion of participant Randomized Randomized controlled trial reaction reported Safe Significant significantly standard care Tablet therapeutic efficacy Trial trials two groups viral disease [DOI] 10.1016/j.ctim.2022.102814 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary Outcomes of Randomized controlled trialShort communication Published on 2022-05-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 신약개발, 임상, [키워드] Ayurveda BNP breathlessness clinical trial coagulative complement Complication control group Controlled trial cough COVID-19 COVID-19 disease creatinine phosphokinase CRP disease Diseases fatigue Hospital stay ICU infective Inflammatory marker integrative medicine intervention group Madhav Rasayan plus management marker Moderate COVID-19 organ outcome parallel group patients patients with moderate Pro Quality of life Randomized controlled trial reduced restored reveal severity significantly standard care statistically significant reduction supplemental oxygen symptoms of COVID-19 Tablet tissue Treatment was reduced [DOI] 10.1016/j.jaim.2022.100590 [Article Type] Short communication
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antiviralsResearch article Published on 2022-05-012022-10-05 Journal: Arab Journal of Gastroenterology [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] addition Antiviral approved clearance Combination COVID-19 COVID-19 infection Cox regression drug Efficacy and safety evaluated Factor Follow-up group highest Infection interval Mild moderate Mortality multicenter negative RT-PCR nitazoxanide Open-label Patient patients with COVID-19 polymerase chain primary endpoint Randomized Randomized controlled trial Result RT-PCR Safe SARS-CoV-2 SCT Serious Adverse Event significantly higher Sofosbuvir/ledipasvir standard care tested therapy three groups Treatment treatment for COVID-19 treatments for COVID-19 viral clearance viral clearance rate was done were recorded [DOI] 10.1016/j.ajg.2022.04.005 [Article Type] Research article
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trialRandomized Controlled Trial Published on 2022-04-272022-10-04 Journal: Trials [Category] 임상, [키워드] 7-point ordinal scale adaptive Adaptive sample size addition Analysis analysis plan angiotensin angiotensin receptor blocker Angiotensin receptor blockers Bayesian Bayesian design benefit blocker CLARITY clinical clinical status clinical trial Controlled coronavirus COVID-19 determine disease Effectiveness Evidence India intention-to-treat principle lung failure patients with COVID-19 Placebo primary analysis Primary outcome protocol randomised controlled randomised controlled trial receptor reducing registry Sample size severity standard care Statistical analysis plan Statistical analysis plan. the WHO Treatment effectiveness Trial Two-arm was selected [DOI] 10.1186/s13063-022-06167-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19초기 경증 내지 중등도의 COVID-19 환자 치료를 위한 소포스부비르/벨파타스비르 조합의 효능 및 안전성Multicenter Study Published on 2022-04-062022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] Antiviral case-control study clearance clinical outcomes Combination conducted Control control group COVID-19 died Disease progression effective evaluated faster HCV Health health problem Infection Intensive median Mild Moderate COVID-19 multicenter nasal swabs once daily one patient oxygen Patient patients PCR performed prevent disease progression primary endpoint RdRP RdRp inhibitor Replication required RNA-dependent RNA polymerase Safe SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection secondary endpoint Side effect sofosbuvir standard care Swab Tablet the patient treat treated Treatment Vaccines velpatasvir Ventilation viral clearance [DOI] 10.1038/s41598-022-09741-5 PMC 바로가기 [Article Type] Multicenter Study
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trialsCOVID-19 환자에서 콜히친의 안전성과 효능: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-04-052022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI age all-cause mortality Analysis anti-inflammatory drug average average age C-reactive protein calculated carried clinical trial clinical trials Colchicine colchicine treatment COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity CRP level CRP levels Cytokine storm D-dimer level D-dimer levels database Diseases effective Efficacy evaluate FIVE Google Scholar Gout inhibiting Interleukins Invasion mean difference mechanical ventilation Meta-analysis no significant difference Odds ratio Odds ratios outcome outcomes P-value p-values Patient random-effects model Randomized randomized control trial RCT RCTs receiving reduce Safety safety profile searched significantly standard care statistically significant systematic review the cytokine storm total population treat Treatment trials [DOI] 10.1371/journal.pone.0266245 PMC 바로가기 [Article Type] Meta-Analysis
The use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial입원한 COVID-19 환자(BeeCovid2)의 보조 치료제로 표준화된 브라질 녹색 프로폴리스 추출물(EPP-AF)의 사용: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Article Published on 2022-04-042022-09-11 Journal: Trials [Category] 임상, [키워드] 1:1 2019 coronavirus disease ACE2 acute COVID-19 Acute kidney injury adjunct Administered adults hospitalized Affect affected age anti-inflammatory agents association Bacterial balloon pump Brazil Cancer patients chronic disease Chronic diseases Chronic kidney disease clinical study conducted coronavirus disease COVID-19 demonstrated diagnosis of COVID-19 double-blinded ECMO Effectiveness Evidence experimental evidence extracorporeal membrane oxygenation Fungal infection groups heart failure HIV patients Hospital stay hospitalized COVID-19 patient hospitalized patients immunoregulation Immunosuppression impacts impossibility include Infection intra-aortic balloon pump Kidney disease Liver disease mechanical ventilation medication moderate moderate to severe outcome PAK1 PAK1 blocker pandemic Patient patients hospitalized Placebo placebo-controlled clinical study pregnant women Primary outcome Propolis protocol randomization Randomized Randomized controlled trial receive reducing renal replacement therapy replacement therapy secondary Secondary infection Secondary outcomes severe liver disease Spread standard care Study protocol Symptom targets TMPRSS2 Treatment Trial vasoactive drugs with COVID-19 [DOI] 10.1186/s13063-022-06176-1 PMC 바로가기 [Article Type] Article
Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical TrialRandomized Controlled Trial Published on 2022-04-012022-10-04 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 임상, [키워드] adverse event Affair age all-cause mortality analyzed androgen antiandrogen Antibiotics Asthma baseline cardiovascular disease Care Cell chronic obstructive chronic respiratory clinical Clinical improvement Clinical outcome common Comorbidity convalescent plasma COVID-19 COVID-19 severity Department determine Dexamethasone diabete disease severity disorder double-blind Effect Efficacy end point End points enrolled Hemodialysis hospital Hospitalization Hospitalized hypertension IMPROVE Inpatient interim analysis intravenous fluids Invasive mechanical ventilation mechanical ventilation median men Mortality no difference no significant difference outcome Patient patients patients randomized Peritoneal dialysis Placebo placebo group placebo-controlled primary end point protease randomization Randomized randomized clinical trial reduce expression Remdesivir requiring supplemental oxygen saline placebo SARS-CoV-2 entry secondary Serious Adverse Event severity of COVID-19 Standard standard care stratified subcutaneous dose supplemental oxygen suppression temperature the placebo group therapy TMPRSS2 Trial usual care vasopressor support veteran with COVID-19 [DOI] 10.1001/jamanetworkopen.2022.7852 PMC 바로가기 [Article Type] Randomized Controlled Trial
Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trialRandomized Controlled Trial Published on 2022-04-012022-10-05 Journal: Lupus [Category] 임상, [키워드] 1:1 95% CI baseline Care Compliance COVID-19 COVID-19 pandemic disease Disease activity evaluate Follow-up Hospitalization in-person visit independent infection risk lupus nephritis Open-label Patient Patient satisfaction proportion Randomized randomized controlled study Randomized controlled trial remained single-center standard care systemic lupus erythematosus telehealth Telemedicine the patient two group [DOI] 10.1177/09612033221084515 PMC 바로가기 [Article Type] Randomized Controlled Trial
Study of the effects of interferon β-1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study입원한 COVID-19 환자에 대한 인터페론 β-1a의 효과 연구: COVIFERON 연구에 대한 SBMU 태스크포스Article Published on 2022-04-012022-09-11 Journal: Journal of medical virology [Category] Coronavirus, COVID19(2023년), SARS, 치료제, [키워드] addition Antiviral conducted control group coronavirus disease Coronavirus disease 2019 COVID-19 died Effect Efficacy group hospital Hospital admission Hospital stay Hospitalized hospitalized COVID-19 patient hospitalized COVID-19 patients hospitalized patient hospitalized patients IFN-β1a immunomodulatory functions IMPROVE indicated innate immune system interferon Interferon β-1a interferons Iran median Mortality mortality rate no statistically significant difference outcome P-value Patient patients treated progression Randomized controlled trial regimen Retrospective study selected Severe case severe cases severe COVID-19 standard care standard treatment statistically statistically significant difference Tehran the interferon two group two groups [DOI] 10.1002/jmv.27475 PMC 바로가기 [Article Type] Article